

## Novel Coronavirus Coding (HERC Recommendations)

The following are the ICD-10-CM codes and procedure codes which may be commonly used for patients with suspected or confirmed COVID-19, along with their placements on the Prioritized List/other HSD files.

These recommendations are from staff of the Health Evidence Review Commission (HERC) and have been updated **March 1, 2021**.

- Placements are from the February 1, 2021 Prioritized List, including errata and changes to incorporate new codes since the original posting.
- In addition, staff recommendations for placement of codes released since 2/1/21 are shown.

This document and the Prioritized List will continue to be updated based on new evidence and information.

### ICD-10-CM codes

Code	Code descriptions	Current Placement <i>(Italicized lines are unfunded)</i>	Notes
B97.29	Other coronavirus as the cause of diseases classified elsewhere	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	To be used as a secondary code
J12.81	Pneumonia due to SARS-associated coronavirus	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
J12.82	Pneumonia due to coronavirus disease 2019	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
J12.89	Other viral pneumonia	304 VIRAL PNEUMONIA	
J20.8	Acute bronchitis due to other specified organisms	459 ACUTE BRONCHITIS AND BRONCHIOLITIS	
J22	Unspecified acute lower respiratory infection	<i>657 RESPIRATORY CONDITIONS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY</i>	
J40	Bronchitis, not specified as acute or chronic	<i>635 CHRONIC BRONCHITIS</i>	
J80	Acute respiratory distress syndrome	233 ADULT RESPIRATORY DISTRESS SYNDROME; ACUTE RESPIRATORY FAILURE; RESPIRATORY CONDITIONS DUE TO PHYSICAL AND CHEMICAL AGENTS	
J98.8	Other specified respiratory disorders	<i>657 RESPIRATORY CONDITIONS WITH NO OR MINIMALLY EFFECTIVE TREATMENTS OR NO TREATMENT NECESSARY</i>	
M35.81	Multisystem inflammatory syndrome (MIS)	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	

**Novel Coronavirus Coding (HERC Recommendations)**

<b>Code</b>	<b>Code descriptions</b>	<b>Current Placement <i>(Italicized lines are unfunded)</i></b>	<b>Notes</b>
R05	Cough	DIAGNOSTIC WORKUP FILE	
R06.02	Shortness of breath	DIAGNOSTIC WORKUP FILE	
R50.9	Fever, unspecified	DIAGNOSTIC WORKUP FILE	
U07.1	COVID-19	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
Z11.52	Encounter for screening for COVID-19	DIAGNOSTIC WORKUP FILE	
Z20.822	Contact with and (suspected) exposure to COVID-19	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
Z20.828	Contact with and (suspected) exposure to other viral communicable diseases	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
Z23	Encounter for immunization	PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
Z86.16	Personal history of COVID-19	INFORMATIONAL DIAGNOSES	

**CPT/HCPCS codes**

<b>Code</b>	<b>Code descriptions</b>	<b>Current Placement <i>(Italicized lines are unfunded)</i></b>	<b>Notes</b>
86318	Immunoassay for infectious agent antibody, qualitative or semiquantitative, single step method (e.g., reagent strip)	Diagnostic Procedure File	Not specific to COVID
86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	Diagnostic Procedure File	
86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen	Excluded File	
86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer	Excluded File	
86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative	Diagnostic Procedure File	
86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	Diagnostic Procedure File	
87426	Infectious agent antigen detection by immunoassay technique (e.g., enzyme	Diagnostic Procedure File	

**Novel Coronavirus Coding (HERC Recommendations)**

<b>Code</b>	<b>Code descriptions</b>	<b>Current Placement <i>(Italicized lines are unfunded)</i></b>	<b>Notes</b>
	immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g., SARS-CoV, SARS-CoV-2 [COVID-19])		
87428	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B	Diagnostic Procedures File	
87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	Diagnostic Procedure File	
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	Diagnostic Procedure File	
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	Diagnostic Procedure File	
87798	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	Diagnostic Procedure File	
87811	Infectious agent antigen detection by immunoassay with direct optical (i.e., visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	Diagnostic Procedure File	

**Novel Coronavirus Coding (HERC Recommendations)**

<b>Code</b>	<b>Code descriptions</b>	<b>Current Placement</b> <i>(Italicized lines are unfunded)</i>	<b>Notes</b>
91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, diluent reconstituted, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	Effective once FDA EUA issued
91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage, for intramuscular use	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
99072	Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
99201-99215, 90832-90853, 90791-90792, Many other codes	Office visits	Covered on most lines Covered for diagnostic purposes regardless of diagnosis  Should be covered by telemedicine/phone when billed per payer guidelines. Other visit/valuation/assessment/therapy codes are covered as well when clinical value approximates in person service. See <a href="#">Guideline Note A5</a>	

**Novel Coronavirus Coding (HERC Recommendations)**

<b>Code</b>	<b>Code descriptions</b>	<b>Current Placement <i>(Italicized lines are unfunded)</i></b>	<b>Notes</b>
99281-99285	ER visits	Same as 99201-99215	
98966-98968, 99441-99443, 99421-99423, 98970-98972, G2061-G2063	Telephone or online assessments/telephone or online evaluation and management services	Covered on most lines Covered for diagnostic purposes regardless of diagnosis  Correct code depends on communication medium and provider type	
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19])	Diagnostic Procedures File	
G2012	Brief communication technology-based service (e.g. virtual check-in) by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related E/M service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion	Similar to telephone codes above  This code can be used for services provided by telephone or synchronous audio/video	
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
M0243	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	399 INFLUENZA, COVID-19 AND OTHER NOVEL RESPIRATORY VIRAL ILLNESS	
Q0239	Injection, bamlanivimab-xxxx, 700 mg	Ancillary Procedures File	Currently not billable as provided by federal gov't
Q0243	Injection, casirivimab and imdevimab, 2400 mg	Ancillary Procedures File	See Q0239
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	Ancillary Procedures File	See Q0239

**Novel Coronavirus Coding (HERC Recommendations)**

**Vaccine therapy administration/ lab codes**

<b>Code</b>	<b>Code descriptions</b>	<b>Current Placement <i>(Italicized lines are unfunded)</i></b>	<b>Notes</b>
U0001	2019 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel (CDC test)	Diagnostic Procedure File	
U0002	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19) using any technique, multiple types or subtypes (includes all targets).	Diagnostic Procedure File	
U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R	Diagnostic Procedure File	
U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCov (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R	Diagnostic Procedure File	
U0005	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	Diagnostic Procedure File	Add on code for CMS
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	

### Novel Coronavirus Coding (HERC Recommendations)

Code	Code descriptions	Current Placement <i>(Italicized lines are unfunded)</i>	Notes
	CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, diluent reconstituted; first dose		
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, diluent reconstituted; second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	
0021A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage; first dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	Effective once FDA EUA issued
0022A	second dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	See 0021A
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage, single dose	3 PREVENTION SERVICES WITH EVIDENCE OF EFFECTIVENESS	

#### HERC's Statement of Intent 6: Telephonic Services During an Outbreak or Epidemic

During an outbreak or epidemic of an infectious disease, reducing administrative barriers (e.g. increasing reimbursement rates) for telephonic evaluation and management services (CPT 99441-99443) and assessment and management services (CPT 98966-98968) is appropriate to ensure access to care while avoiding and preventing unnecessary potential infectious exposure.

#### HERC's Diagnostic Guideline D27: SARS-COV-2 (COVID-19) Testing

Testing for SARS-CoV-2 (COVID-19) virus RNA or viral antigen is a covered diagnostic service.

Antibody testing for SARS-CoV-2 (COVID-19; CPT 86413, 86328 or 86769) is covered as diagnostic only when such testing meets the following criteria:

- A) Testing is done using tests that have FDA Emergency Use Authorization (EUA) or FDA approval;
- AND

## Novel Coronavirus Coding (HERC Recommendations)

- B) Testing is used as part of the diagnostic work up of multisystem inflammatory syndrome in children (MIS-C) or multisystem inflammatory syndrome in adults (MIS-A) for hospitalized persons.

### HERC's Guideline Note 106: Preventive Services (*COVID-19 relevant information is **bolded** below*)

Included on Line 3 are the following preventive services:

- A) US Preventive Services Task Force (USPSTF) "A" and "B" Recommendations in effect and issued prior to January 1, 2020.
- 1) <http://www.uspreventiveservicestaskforce.org/Page/Name/uspstf-a-and-b-recommendations/>
    - a) Treatment of falls prevention with exercise interventions is included on Line 292.
  - 2) USPSTF "D" recommendations are not included on this line or any other line of the Prioritized List.
- B) American Academy of Pediatrics (AAP) Bright Futures Guidelines:
- 1) <http://brightfutures.aap.org>. Periodicity schedule available at [http://www.aap.org/en-us/professional-resources/practice-support/Periodicity/Periodicity Schedule FINAL.pdf](http://www.aap.org/en-us/professional-resources/practice-support/Periodicity/Periodicity%20Schedule_FINAL.pdf).
  - 2) Screening for lead levels is defined as blood lead level testing and is indicated for Medicaid populations at 12 and 24 months. In addition, blood lead level screening of any child between ages 24 and 72 months with no record of a previous blood lead screening test is indicated.
- C) Health Resources and Services Administration (HRSA) Women's Preventive Services-Required Health Plan Coverage Guidelines as updated by HRSA in December 2019. Available at <https://www.hrsa.gov/womens-guidelines-2019> as of September 4, 2020.
- D) Immunizations as recommended by the Advisory Committee on Immunization Practices (ACIP): <http://www.cdc.gov/vaccines/schedules/hcp/index.html> or approved for the Oregon Immunization Program: <https://public.health.oregon.gov/PreventionWellness/VaccinesImmunization/ImmunizationProviderResources/Documents/DMA Pvactable.pdf>
- 1) **COVID-19 vaccines are intended to be included on this line even if the specific administration code(s) do not yet appear on the line when the vaccine has both 1) FDA approval or FDA emergency use authorization (EUA) and 2) ACIP recommendation.**

Colorectal cancer screening is included on Line 3 for average-risk adults aged 50 to 75, using one of the following screening programs:

- A) Colonoscopy every 10 years
- B) Flexible sigmoidoscopy every 5 years
- C) Fecal immunochemical test (FIT) every year
- D) Guaiac-based fecal occult blood test (gFOBT) every year

Colorectal cancer screening for average-risk adults aged 76 to 85 is covered only for those who

- A) Are healthy enough to undergo treatment if colorectal cancer is detected, and
- B) Do not have comorbid conditions that would significantly limit their life expectancy.

The development of this guideline note was informed by a HERC [coverage guidance](https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx). See <https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Evidence-based-Reports.aspx>